Similar to the tumor burden shown in Figure 3B–D, Btz failed to prevent bone loss, while BP-Btz-treated mice had normal bone volume values, similar to the levels in non-MM-bearing mice. The gene discussed is CASC3; the disease is Miyoshi myopathy.